Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford's newest research institute, the Institute of Developmental & Regenerative Medicine (IDRM), has been officially opened, launching the first institute of its kind in the world to physically merge developmental biology and regenerative medicine to treat some of the world's most prolific diseases.

Institute of Developmental & Regenerative Medicine building

The Institute spans three research disciplines, cardiovascular science, neuroscience and immunology, and will foster multidisciplinary collaborations.

The IDRM is based in the IMS-Tetsuya Nakamura Building on Oxford’s Old Road Campus, between Oxford’s hospitals and alongside the University’s world-leading biosciences, engineering and medical research centres.

The IMS-Tetsuya Nakamura Building was supported by a very generous donation from Dr Tetsuya Nakamura, Chief Director of Itabashi Medical System Group (IMS-Group), and substantial fund-raising from the British Heart Foundation.

Bringing together key insights into the brain, the heart and the immune system, world-leading researchers in the IDRM will come together to meet an urgent unmet clinical need. Two thirds of all deaths world-wide are due to non-communicable cardiovascular, neurological or immunology disorders with a developmental origin. The building, which will house around 240 scientists, is designed to encourage collaborative work between research teams with different disciplines to ultimately develop new drugs and therapeutic strategies to tackle these chronic illnesses. The revolutionary design of the building will ensure that scientists from each section regularly cross paths with and can meet others socially in a way that will foster a cross-pollination of ideas and learnings.

Read the full story on the University of Oxford website. 

Similar stories

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead (Weatherall Institute of Molecular Medicine) and Beth Psaila (Weatherall Institute of Molecular Medicine and Oxford Ludwig Institute for Cancer Research), has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs)

Breakthrough in non-invasive liver testing

Two major international studies, including an imaging study led by researchers from the Radcliffe Department of Medicine, have provided new evidence on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, potentially reducing reliance on liver biopsy.

Researchers from the Nuffield Department of Primary Care Health Sciences contribute to parliamentary calls for overhaul of obesity care

Research from the Health Behaviors team has informed a series of parliamentary reports calling for urgent action to tackle obesity in England.

Oxford University invites 100,000 people to take part in a major study of plant-based diets

Researchers at the Nuffield Department of Population Health have launched a major new study designed to generate the most up-to-date picture of different diets in the UK, including plant-based diets, and how they affect long-term health and wellbeing.

Look beyond my skin: your psoriasis could help us understand who develops psoriatic arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

Professor Matthew Wood receives BioUK Special Recognition Award 2026

Professor Matthew Wood, Director and Chief Scientific Officer of the Oxford-Harrington Rare Disease Centre (OHC), has received BioUK’s Special Recognition Award 2026 for his contribution to rare disease research, therapeutic development and the wider life sciences sector.